Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism ; day:27 ; month:11 ; year:2023 ; pages:1-18
Drugs in R & D ; (27.11.2023), 1-18
- Creator
-
Ferri, Nicola
Martin, Sara De
Stuart, James
Traversa, Sergio
Folli, Franco
Pappagallo, Marco
O’Gorman, Cedric
Guidetti, Clotilde
Mattarei, Andrea
Inturrisi, Charles E.
Manfredi, Paolo L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-023-00450-6
- URN
-
urn:nbn:de:101:1-2024021413375681459223
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ferri, Nicola
- Martin, Sara De
- Stuart, James
- Traversa, Sergio
- Folli, Franco
- Pappagallo, Marco
- O’Gorman, Cedric
- Guidetti, Clotilde
- Mattarei, Andrea
- Inturrisi, Charles E.
- Manfredi, Paolo L.
- SpringerLink (Online service)
Other Objects (12)
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction